Trial Profile
Test Phase IV, Multicenter, Open, Aiming to test the difference in efficacy of Natalizumab, Versus Fingolimod the 2 drugs Having A AMM for Treatment of Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms BEST-MS
- 01 May 2020 Status changed from recruiting to completed.
- 01 May 2020 Primary endpoint (Disease free patients) has been met.
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology.